- Financial challenges, including revenue reduction due to manufacturing capacity allocated to clinical trials and supply constraints.
- Supply chain disruptions.
- Need to extend cash runway and secure funding.
- Climate-related risks, including extreme weather events impacting employee productivity and access to raw materials.
- Transition risks, including disruptive climate policies and increased raw material costs.
- Competition for qualified personnel.
Allergy Therapeutics plc
Greenhouse gas emissions & sustainability report data
In its 2024 reporting, Allergy Therapeutics plc disclosed greenhouse gas emissions of 2.7K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
2.7K tCO2e/year
2024
Energy Use
10.2M kWh/year
2024
✅ Reported Environmental Achievements
- Reduced total gross emissions from 3,006 tonnes of CO2e in FY23 to 2,687 tonnes of CO2e in FY24.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Sales recovery
- Initiate recruitment for long-term paediatric trial for Grass MATA MPL
- Improvement in gross margin
📅 Medium-term
- Progression of the VLP Peanut clinical programme towards Phase II
- Proceed with submission for the registration of Grass MATA MPL in EU
- Improvement in EBITDA pre-R&D and exceptionals
🔭 Long-term
- Reduce 95% of total carbon emissions by 2050
🌱 ESG Focus Areas
PatientsPeoplePlanetResponsible Governance